A recent study has suggested that intratumoral delivery of IL21, in combination with anti-HER2 mAb therapy, enhances the therapeutic effects of trastuzumab, skewing tumor-associated macrophages away from a M2 phenotype to a tumor-inhibiting M1 phenotype [34]. Here, IL21 is linked to neoplasm.